BlackRock, Inc. Increases Stake in Cidara Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing an increased ownership in Cidara Therapeutics, Inc. As of September 30, 2025, BlackRock beneficially owns 1,163,607 shares of Cidara Therapeutics' common stock, representing a 4.6% ownership stake. This marks a significant increase from their previous holdings, with a value change of $64,174,873.64 and a shares change of 55,939. The filing indicates that BlackRock acquired these shares in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing also includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.